Ophthalmic Lasers market is Generating Revenue of $1.51 Billion by 2023, at CAGR 4.5% Growth Rate

Ophthalmic Lasers

The use of ophthalmic lasers is expected to increase in the near future, owing to the rise in prevalence of various eye-related diseases globally.

Technological advancements mark a significant trend in the area of ophthalmic lasers, which are expected to propel the growth of the ophthalmic lasers market during the forecast period”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, October 27, 2020 /EINPresswire.com/ — UPDATE AVAILABLE ON-DEMAND

The report on the global ophthalmic lasers market highlights that the market is expected to reach $1,111 million by 2016, from $1,516 million in 2023, growing at a CAGR of 4.5% from 2017 to 2023. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups.

The Covid-19 outbreak has severely affected every sector across the world. The patient numbers have been increasing every day and the majority of the countries are in complete lockdown. This has affected the supply chain and overall business operations. International trading has taken a significant downfall and has created uncertainty in the stock market. These factors have affected the ophthalmic lasers market.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/2013

The photocoagulation lasers segment dominated the global market, accounting for a share of nearly three-fourths of the total market in 2016.

A laser is a device that emits light through a process of optical amplification based on the stimulated emission of electromagnetic radiation. This device is used increasingly in the area of ophthalmology as there is an understanding of laser-tissue interactions in this medical application, such as ophthalmology. This results into use of medical lasers in treating a wide spectrum of eye-related diseases, such as cataract, glaucoma, age-related macular edema, and diabetic retinopathy.

The factors that drive the ophthalmic lasers market are surge in number of eye-related diseases, advancements in the laser technology, and increased awareness for laser application in the area of ophthalmology. However, stringent safety regulations and high rate of failure of surgeries involving use of lasers limit the market growth. Emerging nations, such as LAMEA and Asia-Pacific, and increasing disposable income are expected to provide major opportunities to the manufacturers of ophthalmic lasers.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/2013

The Nd:YAG lasers segment is expected to register highest CAGR of 5.2% from 2017 to 2018. This is attributed to diverse applications of these lasers in the treatment of various eye diseases.

In 2016, North America accounted for a share of two-fifths of the global market, owing to the increase in prevalence of eye-related diseases and high adoption of technologically advanced products. Europe holds the second position in the global ophthalmic lasers market.

The major companies profiled Are:

Carl Ziess Meditec Ag, Novartis AG, Topcon Corporation, Ellex Medical Corporation, Quantel Inc., Iridex Corporation, Nidek Co., LTD., Lumenis, Abbott Laboratories, and Ziemer Ophthalmic Systems.

Access Full Report @ https://www.alliedmarketresearch.com/ophthalmic-laser-market

Similar Reports:

Cosmetic Laser Market Analysis and Industry Forecast, 2027

Biomarker Technologies Market Analysis and Industry Forecast, 2027

U.S. Topical Pain Relief Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Stroke Management Market to Reach Valuation of $36.75 Billion by 2023 | Diagnostics and Therapeutics

Stroke Management

Asia-Pacific is expected to grow with the highest market share during the analysis period and would provide high opportunities for the market players.

Rise in incidences of cardiac disorders, surge in geriatric population, and increased patient awareness drive the growth of the global stroke management market.”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, October 27, 2020 /EINPresswire.com/ — UPDATE AVAILABLE ON-DEMAND

The report on the global Stroke Management market highlights that the market is expected to reach $22,581 million by 2016, from $36,756 million in 2023, growing at a CAGR of 7.1% from 2017 to 2023. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups. The diagnostics segment held more than five-seventh share of the total market in 2016.

The Covid-19 outbreak has severely affected every sector across the world. The patient numbers have been increasing every day and the majority of the countries are in complete lockdown. This has affected the supply chain and overall business operations. International trading has taken a significant downfall and has created uncertainty in the stock market. These factors have affected the Stroke Management market.

The Stroke Management report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/661

Rise in incidences of cardiac disorders, surge in geriatric population, and increased patient awareness drive the growth of the global stroke management market. However, limited insurance coverage along with high cost of devices impede market growth. Nonetheless, improvement in healthcare infrastructure in developing nations would provide lucrative opportunities to new market players in the future.

By type, the diagnostics segment is expected to continue its dominance in the future and occupy almost four-fifths of the overall share by 2023, owing to an increased number of diagnostics procedures for pre-detection of strokes when any signs or symptoms are noticed. The segment is also projected to register the highest CAGR of 8.5% during the forecast period. In addition, the therapeutics segment is poised to grow at a CAGR of 2.9% from 2017 to 2023.

By application, the ischemic stroke segment is expected to dominate the global market and generate more than four-fifths of the overall revenue by 2023. This is attributed to the increase in incidences of ischemic stroke. However, the hemorrhagic stroke segment is projected to grow at the highest CAGR of 7.7% during the forecast period.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/661

Regionally, Asia-Pacific is projected to register the highest CAGR of 8.4% from 2017 to 2023, owing to rise in government healthcare expenditure and growth in demand for healthcare devices from a large pool of patient population, and improvement in healthcare infrastructure. However, North America occupied almost two-fifths of the overall market in 2017 and is expected to continue its dominance through 2023. This is attributed to rise in expenditure to upgrade healthcare systems and growing demand for technologically advanced devices for rapid & accurate distribution of medicines.

The Major Key Players Are:

Abbott Laboratories, B Braun Melsungen AG, Boston Scientific Corp., Bristol-Myers Squibb, Medtronic Plc., Cardinal Health, GE Healthcare, Siemens Healthcare, Glaxosmithkline Plc., and Merck & Company

Access Full Report @ https://www.alliedmarketresearch.com/stroke-diagnostics-and-therapeutics-market

The Other Prominent Players Are:

Mizuho America Inc., Koninklijke Philips N.V., Genentech Inc., Stryker Corporation, ZOLL Medical Corporation, and others.

Similar Reports:

Preimplantation Genetic Testing Market Analysis and Industry Forecast, 2027

Dermatologicals Market Analysis and Industry Forecast, 2027

Cardiac Biomarkers Testing Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Stents Market Growing At A CAGR Of 7.8% And To Target $16.66 Billion By 2022

Stents

Increasing geriatric population and high incidence of heart failures & coronary disorders such as esophageal cancer, gall bladder cancer, & other abnormalities.

In addition, technological advancements in stent systems, such as advent of bioabsorbable stents, have fueled the market growth.”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, October 27, 2020 /EINPresswire.com/ — UPDATE AVAILABLE ON-DEMAND

The report on the global Stents market highlights that the market is expected $16.66 Billion in 2022, growing at a CAGR of 7.8% from 2014 to 2022. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups.

The Covid-19 outbreak has severely affected every sector across the world. The patient numbers have been increasing every day and the majority of the countries are in complete lockdown. This has affected the supply chain and overall business operations. International trading has taken a significant downfall and has created uncertainty in the stock market. These factors have affected the Stents market.

The Stents report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/1603

In 2015, Coronary stents was the largest segment in terms of value, whereas peripheral stents was the dominating market segment in terms of volume. Moreover, coronary stents market is projected to be the fastest growing segment in terms of both, value and volume, during 2016-2022. Asia-Pacific is expected to continue leading the geographic segment during the forecast period.

The coronary stents market has a huge potential with the presence of many players developing innovative technologies. Increasing advancements in the field of interventional cardiology coupled with the progress of minimally invasive techniques have significantly extended the potential of therapeutic applications of stents. Coronary stents such as bare metal stents, drug-eluting stents, and bioabsorbable stents can be used to treat coronary artery diseases (CAD).

Bioabsorbable stent is expected to be the fastest growing segment, registering a CAGR of 37.2% during the forecast period. The major factors fueling the market growth are increasing focus on the development of bioabsorbable stents and their high adoption rate as they can be easily absorbed in the body and do not cause restenosis/thrombosis.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/1603

Metallic biomaterial is the dominant segment due to its cost effectiveness and the efficacy of vascular healing as compared to other stents. Natural biomaterials such as animal or plant origin materials have demonstrated several advantages over synthetic biomaterials. These are biocompatible, nontoxic, may also carry specific protein binding sites, and other biochemical signals that may assist in tissue healing or integration. The global natural biomaterial stents market is expected to grow at a CAGR of 10.5% from 2016 to 2022.

In the current scenario, the U.S. and Europe have the largest customer base for stent implants. However, these regions constitute only 17% share of the world population. Whereas, the Asia-Pacific region constitute around 56.4% of the human population in 2015 (Source: United Nations Department of Economic & Social Affairs); with huge geriatric population; therefore, this region exhibits huge market potential. According to the WHO, the geriatric population in the developing countries is projected to increase by 250% between 2010 and 2050, as compared to 71% in the developed countries. This is expected to increase the patient base in these regions. The Asia-Pacific region accounted for majority of the share in the stents market in 2015, and is expected to maintain this trend throughout the forecast period. This is attributed to the increasing incidence of heart failures, changing lifestyle, improved reimbursement policies, and high adoption of advanced stents in the region.

Access Full Report @ https://www.alliedmarketresearch.com/stents-market

The key players in this market have adopted product development & launch as their key strategies to cater to the changing needs of the industry. Furthermore, companies have collaborated with other key players to develop cost-effective and technologically efficient stents to strengthen their market position.

Similar Reports:

Antimalarial Drugs Market Analysis and Industry Forecast, 2027

Urinary Self-Catheters Market Analysis and Industry Forecast, 2027

Companion Diagnostics Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

InVivo Analytics Issued Patents Regarding Its Core Technology for Optical Tomography And Automated Data Analysis

Body conforming animal mold places the subject in a repeatable position enabling direct alignment of image data to databases.

Body conforming animal mold (BCAM)

The organ probability map is a type of digital anatomical atlas that permits automated image segmentation making applications such as biodistribution analysis of optical images possible.

Organ probability map (OPM)

Patented body-conforming animal mold, organ probability map, and multi-view mirror gantry enable fast optical tomography and automated image data analysis.

The BCAM along with the OPM permit operator-independent preclinical image data analysis and will significantly facilitate the application of machine learning for automated study reporting.”

— Dr. Alex Klose, co-founder and CTO

NEW YORK, NY, UNITED STATES, October 27, 2020 /EINPresswire.com/ — InVivo Analytics® Inc., announces the issuance of US Patents 10,605,742 and 10,575,934 comprising a body-conforming animal mold (BCAM), an organ probability map (OPM), and a mirror gantry for optical tomography of mouse models and automated image data analysis in preclinical research and drug development. These patents cover the company's core technology that seamlessly integrates with its cloud-based preclinical data analysis platform, InVivoAX™.

InVivoAX™ constitutes an image and data visualization tool that can be used with existing preclinical imaging systems, such as optical, PET, SPECT, MRI, and CT. Unlike other commercial image analysis software, InVivoAX enables automated data analysis while eliminating human operator bias and increasing reproducibility. This key functionality is provided by the BCAM, which is an animal shuttle conforming to the body shape of a small animal. Image data congruency is inherently enabled due to its rigid spatial framework that interconnects image pixels/voxels across different animals and study time points. It greatly facilitates monitoring disease progression and longitudinal studies of new therapies. The BCAM and the mirror gantry also enable fast and high-throughput optical tomography because of a full 360° view of optical detection points around the animal. The OPM – a statistical mouse atlas – is spatially aligned with the BCAM and, therefore, can automatically provide advanced anatomical information to optical and nuclear image data sets, e.g. enabling operator independent biodistribution analysis. The OPM also provides tissue absorption and scattering maps that significantly improve the challenging image reconstruction task in optical tomography.

“The power of the BCAM rests in its simplicity of its purpose, that by placing all the subjects in a reproducible position, like a 96-well plate, analysis and alignment from animal to animal, data point to data point, can be done rapidly, reproducibly, and automatically.” Says co-founder and CEO Dr. Neal Paragas.

The BCAM and OPM were validated in a research article titled, “Automated Quantification of Bioluminescence Images,” was published online in the journal Nature Communications.

Importantly, cloud-based data collection is an unlimited reservoir for artificial intelligence (AI) applications. To bridge the biological and digital divide, InVivoAX creates a global image data resource by collating image data into data repositories with spatial data point congruency. These large pools of datasets – globally shared within user teams or institutions on our InVivoAX platform – will feed neural networks for training and will commence the next generation of preclinical image analysis.

Ultimately, InVivoAX eliminates operator variability, increases reproducibility, and automates unbiased image data quantification across different animals, time-points, and modalities. It is the first platform system to transfer preclinical imaging data to the cloud where operator independent data analysis is performed. Most importantly, applications for this technology represent the most urgent fields ranging from T-cell biodistribution in immuno-oncology studies, organ burden in infectious disease models, gene and cell delivery efficacy for therapeutic development. Overall, this cloud-based system will offer interconnectivity of existing imaging systems for automated data analysis, multimodal image co-registration, and data sharing.

InVivo Analytics is dedicated to building novel tools to assist scientists unlocking the cures of the future.

About In Vivo Analytics
Spun-out of Columbia University and fueled by grants from the National Institutes of Health (NIH), InVivo Analytics develops preclinical imaging solutions which transform current small animal imaging systems into a fully automated cloud-based image data analysis platform. The platform is operator independent, and yields quantitative and reproducible data for preclinical research and drug discovery.

Media Contact
media@invivoax.com

Neal Paragas
InVivo Analytics, Inc.
email us here


Source: EIN Presswire

The NCIDC Announces Its Members are In-Network for the NC State Employee Health Plan's Clear Pricing Network for 2021

The NCIDC is the largest clinically integrated network of independent dermatologists in the state

CARY, NC, UNITED STATES, October 27, 2020 /EINPresswire.com/ — The North Carolina Independent Dermatology Collaboration, a leading clinically integrated dermatology healthcare provider collaboration in the state, announced that its members are in the NC State Health Plan Network for its 2021 launch in North Carolina. The NCIDC has developed plans that align with the State Health Plan's mission to make healthcare more affordable and focus on patients getting better access to independent dermatologists and all the subspecialties of dermatology and improving the quality of dermatologic care.

The main goal of the Clear Pricing Project is to provide a fair and transparent network for members while preserving and protecting the Plan's financial sustainability.

To help members control their health costs and support Clear Pricing Project (CPP) providers, the State Health Plan adds new copay waivers and reductions for 2021. If a member selects a Clear Pricing Project provider as their Primary Care Provider listed on their ID card, their visits are free. If the member visits a Clear Pricing Project specialist, 80/20 Plan members will pay only $40 for a CPP specialist ($80 for a non-CPP specialist), and 70/30 Plan members will pay $47 for a CPP specialist ($94 for a non-CPP specialist).

Many of North Carolina's independent dermatology physician groups have formed a regional collaborative designed to allow them to provide the benefits of a clinically integrated collaboration, including higher efficiency of care, improved quality, more effective delivery, lower costs, and increased savings.

The organization, dubbed the North Carolina Independent Dermatology Collaborative, brings together many dermatology care providers spanning the Triangle area of North Carolina. The physicians have built an organization for independent physicians by physicians to allow the participating physicians to achieve the advantages of being part of a more extensive, clinically integrated system. Member physician practices will facilitate lowering costs while providing high-quality care with the same hometown doctor patients have come to know and trust — all without sacrificing their independence.

The founding members of the Collaborative, in addition to its large general dermatology care base, offers a broad range of dermatology specialties, from Dermatopathology to Pediatric Dermatology and Dermatologic surgery, including Mohs surgery to Cosmetic Dermatology and much more.

Dubbed the North Carolina Independent Dermatology Collaborative, the entity comprises 24 independent dermatology providers who serve estimated 250,000-plus patients in the area. Formed during increasing healthcare consolidation and value-based care models, the collaborative intended to provide higher efficiencies at lower costs than other dermatology providers can offer and a total dermatologic soluti

Parker Eales
North Carolina Independent Dermatology Collaboration
+1 9193034053
email us here


Source: EIN Presswire

Pharmaceutical Compliance Software Market 2020 – Key Application, Opportunities, Demand, Trends, Share, Forecast 2025

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

PUNE, INDIA, October 27, 2020 /EINPresswire.com/ — This report has been prepared based on extensive research and analysis of the latest dominating trends in the market. The global Pharmaceutical Compliance Software market has been studied and focus has been on the volume and value of the product/service as well as the manufacturing methods employed. It contains a brief overview of the competitive scene of the key players along with the market introduction and research objectives for the forecast period from 2020 to 2025. The report also presents the market size by observing the historical data and the prospects of the product/service. The economic indicators and the market research methodology have also been provided further in the global Pharmaceutical Compliance Software market report.

Get a Free Sample Report on Pharmaceutical Compliance Software Industry Outlook@ https://www.wiseguyreports.com/sample-request/5976525-global-pharmaceutical-compliance-software-market-growth-status-and

According to this study, over the next five years the Pharmaceutical Compliance Software market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Pharmaceutical Compliance Software business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Pharmaceutical Compliance Software market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Pharmaceutical Compliance Software, covering the supply chain analysis, impact assessment to the Pharmaceutical Compliance Software market size growth rate in several scenarios, and the measures to be undertaken by Pharmaceutical Compliance Software companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
Cloud-Based Pharmaceutical Compliance Software
On-Premise Pharmaceutical Compliance Software

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
Product Information Management
Pharmaceutical Electronic Registration

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Ideagen
Qordata
ACUTA
Lachman Consultant Services
Sparta Systems
Wolters Kluwer
LogicGate
Intagras
Bwise
LogicManager
Qualsys
QUMAS
Med-Script
MasterControl
Axway

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Table of Content

1 Scope of the Report

2 Executive Summary

3 Global Pharmaceutical Compliance Software by Players

4 Pharmaceutical Compliance Software by Regions

5 Americas

6 APAC

7 Europe

8 Middle East & Africa

9 Market Drivers, Challenges and Trends

10 Global Pharmaceutical Compliance Software Market Forecast

11 Key Players Analysis

12 Research Findings and Conclusion

……Continued

Ask Any Query on Pharmaceutical Compliance Software Market Size, Share, and Volume@ https://www.wiseguyreports.com/enquiry/5976525-global-pharmaceutical-compliance-software-market-growth-status-and

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

Hospital Software Global Market 2020 – Key Application, Opportunities, Demand, Status, Trends, Share, Forecast 2025

This report covers market characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies

PUNE, INDIA, October 27, 2020 /EINPresswire.com/ — This report has been prepared based on extensive research and analysis of the latest dominating trends in the market. The global Hospital Software market has been studied and focus has been on the volume and value of the product/service as well as the manufacturing methods employed. It contains a brief overview of the competitive scene of the key players along with the market introduction and research objectives for the forecast period from 2020 to 2025. The report also presents the market size by observing the historical data and the prospects of the product/service. The economic indicators and the market research methodology have also been provided further in the global Hospital Software market report.

Get a Free Sample Report on Hospital Software Industry Outlook@ https://www.wiseguyreports.com/sample-request/5976346-global-hospital-software-market-growth-status-and-outlook-2020-2025

According to this study, over the next five years the Hospital Software market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Hospital Software business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Hospital Software market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Hospital Software, covering the supply chain analysis, impact assessment to the Hospital Software market size growth rate in several scenarios, and the measures to be undertaken by Hospital Software companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.
EHR/EMR
Medical CRM
Websites and Patient Portals
Other

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.
Private Hospital
Public Hospital

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
eClinicalWorks
NextGen Healthcare
McKesson
Allscripts
Athena Health
Cerner Corp
Quest Diagnostics (DELL)
GE Healthcare
Optum Health
Epic Systems Corp
Meditech
Computer Programs and Systems
Compugroup Medical
Practice Fusion
Merge Healthcare (IBM)
Carestream Health
Agfa HealthCare
Sunquest Information Systems
Greenway Health
Lexmark Healthcare
Winning Health Technology
Neusoft

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Table of Content

1 Scope of the Report

2 Executive Summary

3 Global Hospital Software by Players

4 Hospital Software by Regions

5 Americas

6 APAC

7 Europe

8 Middle East & Africa

9 Market Drivers, Challenges and Trends

10 Global Hospital Software Market Forecast

11 Key Players Analysis

12 Research Findings and Conclusion

……Continued

Ask Any Query on Hospital Software Market Size, Share, and Volume@ https://www.wiseguyreports.com/enquiry/5976346-global-hospital-software-market-growth-status-and-outlook-2020-2025

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
646-845-9349
email us here


Source: EIN Presswire

CORONA STUDY USING DELTAREX-G FOR COVID-19

Graphic illustration of DeltaRex-G vector. The DeltaRex-G vector displaying disease targeting peptide (A), for binding to exposed collagenous (XC) proteins in COVID-19 diseased sites (B), and encoding a gene for killing immune cells causing ARDS

Available now: “Right to Try” DeltaRex-G for COVID-19 EMERGENCY USE

DeltaRex-G is the first, and so far, only, disease-targeted gene therapy that has the potential of effectively treating COVID-19 induced Cytokine Storm and Respiratory Distress Syndrome”.”

— Erlinda M. Gordon, M.D.

LOS ANGELES, CA, UNITED STATES, October 27, 2020 /EINPresswire.com/ — The Aveni Foundation is proud to announce its new mission to treat COVID-19 induced pneumonia/Acute Respiratory Distress Syndrome , as presented by Dr. Erlinda M. Gordon, President of the Aveni Foundation, at the recent COVID-19 Symposium sponsored by the American Society of Gene and Cell Therapy. According to Dr. Gordon, “DeltaRex-G is the first, and so far, only, disease-targeted gene therapy that has the potential of effectively treating COVID-19 induced Cytokine Storm and Respiratory Distress Syndrome”.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This aggressive and highly infectious virus can lead to life threatening complications including cytokine storm (raging fevers, headaches, intense fatigue, muscle aches, loss of taste and smell) and acute respiratory distress syndrome (difficulty breathing from pneumonia leading to respiratory failure). These complications are the main causes of death in this global pandemic. However, these complications are believed to be caused not by the virus itself, but by an exaggerated immune reaction to the infection. The overactive immune cells are thought to make certain proinflammatory chemicals (cytokines) that cause raging fevers and damage to the lungs and other organs.

Over 1000 clinical trials are on-going worldwide to diagnose, treat, and improve the rate of recovery from COVID-19. So far, there are a few promising drugs but no FDA-approved treatment for COVID-19. We announce DeltaRex-G, the first, and so far, only, gene therapy for treatment of COVID-19 induced Cytokine Storm and Respiratory Distress Syndrome.

WHY DELTAREX-G FOR COVID-19?

1) DeltaRex-G has a navigational system that seeks out areas of injury (e.g. inflamed lung), thus increasing the drug concentration in injured sites, where overactive immune cells are creating havoc. Our hypothesis is that DeltaRex-G can hasten recovery from pneumonia/ARDS and prevent chronic lung disease by killing the activated immune cells causing ARDS and the proliferative fibroblasts causing chronic lung disease;

2) DeltaRex-G has been given to over 280 cancer patients with few, if any, toxic side effects; and

3) DeltaRex-G is already FDA approved for the Foundation’s “Right-to-Try” Expanded Access Program as treatment of Stage 4 cancer.

WHAT IS THE STUDY ABOUT?

The CORONA STUDY is a Phase 1/2 study that will test whether DeltaRex-G is safe, will improve the symptoms of COVID-19, will hasten patient recovery from pneumonia/ARDS and will prevent chronic lung disease induced by COVID-19.

The Aveni Foundation (www.avenifoundation.org) is raising $5 Million USD for this upcoming study: The CORONA study Using DeltaRex-G for COVID-19 (www.clinicaltrials.gov: NCT04378244). However, available now is a limited supply of DeltaRex-G for “Right to Try” EMERGENCY USE.

TO DONATE: go to www.avenifoundation.org, click on CONTRIBUTE, or write a check payable to: Aveni Foundation, 2811 Wilshire Blvd., Suite 777, Santa Monica CA 90403; or Wire funds to: Chase Bank, Account Name: Aveni Foundation, Routing No: 322 271 627, Checking Acct. No.: 317 312 673, SWIFT CHASUS33.

For more information, email Dr. Gordon at egordon@avenifoundation.org or egordon@sarcomaoncology.com.

Erlinda Maria Gordon
Aveni Foundation
+1 818-726-3278
email us here

Erlinda M. Gordon, MD- DeltaRex-G Targeted Gene Therapy for COVID-19


Source: EIN Presswire

Transpersonal Psychologist Dr. Sheila Krystal to be Featured on Close Up Radio

BERKLEY, CALIFORNIA, UNITED STATES, October 27, 2020 /EINPresswire.com/ — Right now, the collective human race is concerned with the COVID-19 pandemic. Loved ones are getting sick. People are suffering from financial distress. Some are paralyzed by fear. Others are angry or depressed.

But there are silver linings in this dark cloud. We must refocus our attention in ways that are productive instead of destructive. What we pay attention to most determines our emotions and mood. We can stay optimistic, more positive, more centered, when we work with our brain’s neuroplasticity.

“When we all go to sleep at night, we are awash in the collective unconscious, which since COVID-19, contains fear, anger, impatience and depression,” says transpersonal psychologist Dr. Sheila Krystal. “Many of us wake up afraid. Some are even having panic attacks, and the sympathetic nervous system is on full blast. My hope is to help people know what to do when that happens.”

According to Dr. Krystal, psychological work must include all 4 dimensions: the physical body (improving health, diet, exercise, sleep), the emotional plane and autonomic nervous system regulation, the mental realm and quieting the monkey mind and finally the spiritual dimension promoting more reliance on the inner world and on mindfulness.

“People don’t have to be victims of their conditioning and past and trauma,” says Dr. Krystal. “We now understand that the brain can change itself, and we can participate in that change by focusing our attention on the present moment and what is positive in our lives and count our blessings. If we focus only on gratitude and appreciation for a minimum of thirty seconds, we can participate in our brain’s neuroplasticity and create and reinforce new neural networks for optimism, positivity and compassion.”

Indeed, the virus has given us the opportunity to reexamine our priorities. Dr. Krystal recommends finding a therapist who offers eye movement desensitization and reprocessing (EMDR) and mindfulness training, especially for trauma.

“I work with meditation, centering self-awareness techniques, visualization, CBT and EMDR with clients,” says Dr. Krystal.

Close Up Radio will feature Dr. Sheila Krystal in an interview with Jim Masters on October 29th at 2pm EST

Listen to the show on BlogTalkRadio

If you have any questions for our guest, please call (347) 996-3389

Lou Ceparano
Close Up Television & Radio
+ +1 (631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Historic Billion-Dollar Settlement Renews Hope for Those Struggling With Opioid Use

Waismann Method® Advanced Treatment of Opiate Dependence

Waismann Method® Advanced Treatment of Opiate Dependence

Clare Waismann, Certified Addiction Treatment Counselor, founder of Waismann Method® and Domus Retreat®

Clare Waismann, Certified Addiction Treatment Counselor, founder of Waismann Method® and Domus Retreat®

Michael Lowenstein, M.D., Waismann Method® Medical Director

Michael Lowenstein, M.D., Waismann Method® Medical Director

A historic settlement against OxyContin maker, Purdue Pharma, can provide financial relief plus well-deserved justice for the victims of the opioid crisis.

May [the money] provide those who desire to come off opioids the ability to receive adequate medical care through the withdrawal phase, followed by the necessary professional mental health support.”

— Clare Waismann

BEVERLY HILLS, CALIFORNIA, UNITED STATES, October 27, 2020 /EINPresswire.com/ — On Wednesday, the Justice Department announced that OxyContin-maker Purdue Pharma agreed to plead guilty to three felony criminal charges including violating the anti-kickback laws and conspiracy to defraud the United States. The historic $8.3 billion settlement — the largest such settlement ever reached with a pharmaceutical company — is the result of a years-long criminal investigation. The penalties include a criminal fine of $3.544 billion. Purdue must make a direct payment of $225 million to the government as part of a larger $2 billion criminal forfeiture.

The Sackler family will lose control over their company. Subject to approval by the bankruptcy court of the Southern District of New York, the company would cease to operate in its current form and would be governed by a trust as a public benefit company (PBC). The trust is designed to benefit the American public. The Department of Justice is willing to credit up to $1.775 billion against the $2 billion and channel that to State and local governments.

Jeff Rosen, Deputy Attorney General, said that this settlement “will redress past wrongs, and will also provide extraordinary new resources for treatment and care of those affected by opioid addiction.”

Compensating victims and funding effective treatment centers is the right thing to do, and it makes sense economically. The CDC estimates that the total “economic burden” of opioid misuse in this country is about $78.5 billion each year.

Clare Waismann, the founder of Waismann Method® Advanced Treatment of Opiate Dependence and Domus Retreat, is hopeful these funds will make a difference in victims’ lives.

“May the money be used wisely to educate, prevent, and treat our citizens. May it also provide those who desire to come off opioids the ability to receive adequate medical care in a hospital through the withdrawal phase, followed by the necessary professional mental health support,” Clare said.

This settlement can provide a financial reward, and some well-deserved justice for those individuals who became victims of the opioid crisis.

Individuals continue to seek numbing devices to self-medicate the emotional distress that continuously overwhelms them. Convincing people that they are “addicts” or have an “addictive personality” is unproductive and harmful.

We need to see them, hear them, and, most of all, understand their struggles. Let us replace condemnation with education, mental health care, and medical treatment when needed. Only then, will we really start saving lives.

For more information about Waismann Method®, please visit www.opiates.com. For interviews, contact Clare Waismann at 800-423-2482 or send an email to info@opiates.com.

About Waismann Method® Opioid Treatment Specialists

Clare Waismann is the founder of Waismann Method® and is a Certified Addiction Treatment Counselor. For over 21 years, Waismann Method® has successfully treated thousands of patients struggling with opioid use disorder. Clare has spent over two decades tirelessly fighting to increase access to medically-assisted detox, mental health care and to end the unjust stigma associated with opioid use disorder.

Waismann Method® provides opioid users with the highest level of individualized medical-based detoxification treatment. The center’s medical director, Dr. Michael H. Lowenstein, is a quadruple board-certified M.D. He is highly recognized for his expertise in medically-assisted opioid treatment (including rapid detox), the successful management of pain, and anesthesiology. Trusted since 1998, patients from around the world have come to the facility located exclusively in Southern California for treatment of opioid dependence in a private, full-service accredited hospital.

Clare Waismann
Waismann Method
+1 800-423-2482
info@opiates.com
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire